ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

Ruderfer Douglas M*; Charney Alexander W; Readhead Ben; Kidd Brian A; Kahler Anna K; Kenny Paul J; Keiser Michael J; Moran Jennifer L; Hultman Christina M; Scott Stuart A; Sullivan Patrick F; Purcell Shaun M; Dudley Joel T; Sklar Pamela
Lancet Psychiatry2016-4DOI: 10.1016/S2215-0366(15)00553-2
2被引15阅读
引用收藏
分享

摘要

Background Therapeutic treatments for schizophrenia do not alleviate symptoms for all patients and efficacy is limited by common, often severe, side-effects. Genetic studies of disease can identify novel drug targets, and drugs for which the mechanism has direct genetic support have increased likelihood of clinical success. Large-scale genetic studies of schizophrenia have increased the number of genes and gene sets associated with risk. We aimed to examine the overlap between schizophrenia risk loci and gene targets of a comprehensive set of medications to potentially inform and improve treatment of schizophrenia. <br>Methods We defined schizophrenia risk loci as genomic regions reaching genome-wide significance in the latest Psychiatric Genomics Consortium schizophrenia genome-wide association study (GWAS) of 36 989 cases and 113 075 controls and loss of function variants observed only once among 5079 individuals in an exome-sequencing study of 2536 schizophrenia cases and 2543 controls (Swedish Schizophrenia Study). Using two large and orthogonally created databases, we collated drug targets into 167 gene sets targeted by pharmacologically similar drugs and examined enrichment of schizophrenia risk loci in these sets. We further linked the exome-sequenced data with a national drug registry (the Swedish Prescribed Drug Register) to assess the contribution of rare variants to treatment response, using clozapine prescription as a proxy for treatment resistance. <br>Findings We combined results from testing rare and common variation and, after correction for multiple testing, two gene sets were associated with schizophrenia risk: agents against amoebiasis and other protozoal diseases (106 genes, p=0.00046, p(corrected) = 0.024) and antipsychotics (347 genes, p=0.00078, p(corrected)=0.046). Further analysis pointed to antipsychotics as having independent enrichment after removing genes that overlapped these two target sets. We noted significant enrichment both in known targets of antipsychotics (70 genes, p=0.0078) and novel predicted targets (277 genes, p=0.019). Patients with treatment-resistant schizophrenia had an excess of rare disruptive variants in gene targets of antipsychotics (347 genes, p=0.0067) and in genes with evidence for a role in antipsychotic efficacy (91 genes, p=0.0029). <br>Interpretation Our results support genetic overlap between schizophrenia pathogenesis and antipsychotic mechanism of action. This finding is consistent with treatment efficacy being polygenic and suggests that single-target therapeutics might be insufficient. We provide evidence of a role for rare functional variants in antipsychotic treatment response, pointing to a subset of patients where their genetic information could inform treatment. Finally, we present a novel framework for identifying treatments from genetic data and improving our understanding of therapeutic mechanism.

相关
加载中…
  • Exploring Lead loci shared between schizophrenia and Cardiometabolic traits
    He, Qian; Bennett, Adam N.; Liu, Jundong; Fan, Beifang; Han, Xue; Cheng, Lu; Chen, Yan; Yang, Xia; Chan, Kei Hang Katie*BMC GENOMICS, 2022, 23(1): 617.被引 1
  • What Next in Schizophrenia Genetics for the Psychiatric Genomics Consortium?
    Corvin Aiden*; Sullivan Patrick FSCHIZOPHRENIA BULLETIN, 2016, 42(3): 538-541.
  • Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia
    Su, Yi; Yu, Hao; Wang, Zhiren; Liu, Sha; Zhao, Liansheng; Fu, Yingmei; Yang, Yongfeng; Du, Bo; Zhang, Fuquan; Zhang, Xiangrong; Huang, Manli; Hou, Cailan; Huang, Guoping; Su, Zhonghua; Peng, Mao; Yan, Ran; Zhang, Yuyanan; Yan, Hao; Wang, Lifang; Lu, Tianlan; Jia, Fujun; Li, Keqing; Lv, Luxian; Wang, Hongxing; Yu, Shunying; Wang, Qiang; Tan, Yunlong; Xu, Yong; Zhang, Dai; Yue, WeihuaBJPsych Open, 2021, 7(4): e121.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Lancet Psychiatry
发表日期
2016-04
卷期
第 3 卷, 第 4 期
页码
350-357
DOI
10.1016/S2215-0366(15)00553-2
语言
ENGLISH
成果收录
SSCI
资助标注
US National Institutes of Health

作者

  • R

    Ruderfer Douglas M (通讯) (第一作者)

  • C

    Charney Alexander W

查看全部 14 位作者收起作者
  • R

    Readhead Ben

  • K

    Kidd Brian A

  • K

    Kahler Anna K

  • K

    Kenny Paul J

  • K

    Keiser Michael J

  • M

    Moran Jennifer L

  • H

    Hultman Christina M

  • S

    Scott Stuart A

  • S

    Sullivan Patrick F

  • P

    Purcell Shaun M

  • D

    Dudley Joel T

  • S

    Sklar Pamela

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417